Why is feasibility so important?

Feasibility is often underestimated — yet it determines whether a study will stay on schedule or start facing delays within months.

Biostat® emphasises that feasibility is an investment.
It prevents issues that later become difficult or impossible to fix.

Feasibility assessment covers:

• patient population size and availability,
• investigators’ experience,
• diagnostic and IT infrastructure,
• staffing levels (nurses, coordinators, pharmacists),
• competing studies and site load,
• administrative capacity.

The final report indicates:

• best-fit sites,
• recruitment limitations,
• recommended mitigation steps.

Common sponsor mistake

Choosing sites based on personal relationships instead of feasibility data.
This often results in:

• slow recruitment,
• lack of patient availability,
• inexperienced staff,
• data quality issues,
• or even temporary study suspension.

How does Biostat® conduct feasibility?

We use dedicated tools:

• eFeasibility — platform for collecting site surveys,
• eSiteLog — system tracking site activity and status.

Analyses take from several days to two weeks and result in a structured, documented recommendation.

Outcome of high-quality feasibility

• fast site activation,
• stable early recruitment,
• minimal risk of delays,
• full MDR and GCP compliance.

If you are planning a new study, contact us early.
We will perform feasibility, identify ideal sites and help launch your project efficiently and safely.